tumors accumulate thousands of mutations. Technological advances have enabled 24 whole genome sequencing of these mutations in large cohorts, such as those from the Pancancer 25 Analysis of Whole Genomes (PCAWG) Consortium. The resulting data explosion has led to 26 many methods for detecting cancer drivers through mutational recurrence and deviation from 27 background mutation rates. However, these methods require a large cohort and underperform 28 when recurrence is low. An alternate approach involves harnessing the variant allele frequency 29 (VAF) of mutations in the population of tumor cells in a single individual. Moreover, ultra-deep 30 sequencing of tumors, which is now possible, allows for particularly accurate VAF 31 measurements, and recent studies have begun to use these to determine evolutionary trajectories 32 and quantify subclonal selection. Here, we developed a method that quantifies tumor growth and 33 driver effects for individual samples based solely on the VAF spectrum. Drivers introduce a 34 perturbation into this spectrum, and our method uses the frequency of "hitchhiking" mutations 35 preceding a driver to measure this perturbation. Specifically, our method applies various growth 36 models to identify periods of positive/negative growth, the genomic regions associated with 37 them, and the presence and effect of putative drivers. To validate our method, we first used 38 simulation models to successfully approximate the timing and size of a driver's effect. Then, we 39 tested our method on 993 linear tumors (i.e. those with linear subclonal expansion, where each 40 parent-subclone has one child) from the PCAWG Consortium and found that the identified 41 periods of positive growth are associated with drivers previously highlighted via recurrence by 42 the PCAWG consortium. Finally, we applied our method to an ultra-deep sequenced AML tumor 43 and identified known cancer genes and additional driver candidates. In summary, our method 44 presents opportunities for personalized diagnosis using deep sequenced whole genome data from 45 an individual. 46 48
Introduction

147
Our framework's equations (which we dub "hitchhiker equations", see Supplement) relate the 148 VAF of generational hitchhiker mutations to the fitness effect of the subclonal driver with which 149 they are hitchhiking, mediated by various growth and population parameters (i.e. the base growth 150 rate r, a scalar multiplier k corresponding to fitness effect of the mutation, the time t1 when the 151 driver mutation is generated, Ntot the population size and NF the driver's subclone size). The 152 existence and fitness effects of subclonal drivers are not directly observable but are of primary 153 biomedical importance. The VAF of hitchhiker mutations is directly observable, therefore we 154 chose to use these VAFs to infer the presence of subclonal drivers and estimate their fitness 155 effects. Our approach is to fit the known VAFs of the hitchhiker mutations in the hitchhiker 156 equations to estimate the growth pattern and the fitness effect of subclonal drivers. This method 8 from idealized behavior, we make use of sliding windows and local timepoint re-optimizations in 160 the parameter estimation to prevent departures from idealized behavior in one part of the VAF 161 spectrum from interfering with parameter estimation in other parts of the VAF spectrum. The 162 details of the growth and population parameters, their estimation, and the use of sliding windows 163 are described in the Supplement. We derived our estimators for r and k through the 164 implementation of a deterministic model to a stochastic process with a large final population 165
Ntot. 166 167
Modeling the frequency of g-hitchhikers using exponential models 168
We assume a simple and neutral population of cancer cells that grows exponentially with rate r. 169
For simplicity, we here assign each new daughter cell one new mutation (alternative mutation 170 rates do not affect the derivation, see Supplement). At time t1, a mutation occurs that accelerates 171 the growth rate of the specific subpopulation by a scalar multiplier k such that the new 172 population expands with new rate k×r. At the time of biopsy T=t1+t2, where the fitness mutation 173 occurs at t1 and expands for time t2, we expect the frequency of a generational g-hitchhiker 174 mutation that occurred at time tm < t1 (see Figure 1 where E(F,1 @ ) is the frequency of the driver mutation occurring at t1 and expanding for t2=T-t1, 182
The terms { e <I1 7 * J N 121 − E(F,1 @ ) * N 121 L } and { E(F,1 @ ) * N 121 } correspond to the growth of 183 regular Nand fitness N / populations respectively, while extracting N -/ ={ N E(F,1 @ ) * N 121 C } for 184 not double-counting the hypothetical regular growth of fitness cells (see Figure 1 , Supplement). 185 186 Equation (1) for the m-th hitchhiker implicitly allows one to use the previous m-1 potential 187 hitchhikers to refine the estimates of growth rate r and scalar effect k. This estimation is achieved 188 either through a non-linear-least-squares optimization, and/or through the independent 189 calculation of growth r. 190
191
The frequency of g-hitchhiking mutations follows the form of an exponential distribution. 192
Theoretically, this further allows us to estimate growth rate r from consecutive g-hitchhiking 193 mutations m1, m2, and m3, which occurred at times tm1, tm2, and tm3 (tm1, tm2, and tm3 < t1), 194 according to 195
In practice, to obtain more accurate estimates, our default algorithm estimates the growth rate r 199 from three more distant time points t, t+n, and t+m (n<m and t+m< t1) with final frequencies 200 # (T, t), # (T, t W ), and # (T, t ( ), respectively, as described in the Supplement. 201
202
In addition to our independent estimate of growth rate r, and in order to avoid previous 206 frequency perturbations in our sample and localize the effect timewise, we also include an extra 207 parameter referred to as 'generational time (tg)', which allows us to calibrate an offset for the 208 number of past generations until that point without considering previous mutations outside our 209 sliding window. First, we tested our algorithm on simulated data based on various growth models, including: a) 222 exponential growth, b) exponential growth with delayed cell division, and c) logistic growth 223 (birth and death model). We performed simulation models (a) and (c) using a stochastic Gillespie 224 algorithm, whereas model (b) represents an exponential cell growth model with a lag time for 225 cell division, which prevents a cell from re-dividing immediately. Briefly, for the "Birth and 226 branching process to model the growth of a single transformed cell into a tumor with a dominant 228 subclone. At each time step, an event type is chosen with a probability proportional to the event's 229 prevalence (see supplement) Then, a cell of the eligible type is randomly chosen to undergo that 230 event. In our logistic-growth simulations, the death rate of each cell climbs proportionally as 231 carrying capacity is reached, whereas in our exponential simulations, the death rate of each cell 232 is constant throughout the simulation. The simulation ends randomly, after the driver subclone 233 reaches a critical prevalence (see supplement for more details). The Gillespie algorithm has been 234 frequently used to simulate stochastically dividing cells 48-54 , although simulations with special 235 attention to cell cycle have also been recommended 55 . 236
237
During simulated growth, we assigned a "driver" mutation with additional propagating effects 238 from nearly neutral to high (k=1.1, 2, 3, and 4), thus leading to faster growth for the respective 239 subpopulation that contains the specific mutation. Using conservative assumptions, these scalar 240 values represent a range of projected selection coefficients s* from 0.001 to 0.03 in biologically 241 sized populations (see Supplement). For each simulation, we calculated each mutation's 242 frequency in the total population and ordered them based on that frequency. Then, by applying 243 our method we calculated the ranking distance D (as the number of ordered mutations) between 244 the true and our predicted driver (growth peak), as well as the driver's scalar effect k. 245
246
We tested our method's performance in simulated tumors of lower coverage and different 247 effects. Higher sequencing depth and scalar effect k provided more accurate results and improved 248 our method's implementation (Figure 2a ,b). Lower coverage was associated with worse k 249 calculations and driver predictions, as well as lower positive predictive values (PPVs). For weak 12 drivers, low sequencing coverage made their identification more difficult. Absolute median 251 ranking distance |D| c was 41 for coverage 100x/k=2, compared to 13 for coverage 1000x/k=2 and 252 |D| c =11 for coverage 1000x/k=4 respectively. In general, driver identification required either a 253 higher than 100x coverage, or a stronger effect (i.e. k>2, s* >0.01 for a projected cell population 254 of 1,000,000 cells) ( Figure 2i ). 255 256 Overall, we were able to well approximate the driver's occurrence and effect ( Figure 2 ). For the 257 birth and death model with simulated coverage 1,000x, the median predicted estimation for 258 simulated effects k=2, k=3, and k=4 was 2.3, 2.9, and 3.8, respectively (Figures 2ii, S6b). 259
Moreover, the median ranking distance D d between simulated and predicted drivers with effect 260 k=1.1 (nearly neutral), k=2, and k=3 was 71, 3. 5, and 6, respectively. The corresponding median 261 distances for random mutations were 73, 43, and 41 ( Figure S1c ). For our nearly neutral 262 simulations (k = 1.1, s* ~ 0.001 for a projected cell population of 1,000,000 cells) the median 263 distance D d in driver predictions and random predictions was very similar and not significant. included added stochasticity with varying mutation rates during tumor progression ( ̅ =10 272 mutations per cell division). For every simulation, both neutral and non-neutral, we identified our model's highest predicted effect peak, calculated the effect k and absolute median ranking 274 distance |D d | between the simulated and predicted driver in number of ranked mutations. Various 275 scenarios for non-neutral growth included a wide range of simulated selection coefficients s (0 to 276 33, for a population size of 10,000 cells), categorized driver's VAF (small 0.1-0.2 ; medium 0.2-277 0.3 ; large 0.3-0.4) and larger cell population projections using population genetic models and 278 method adjustments. Corresponding neutral simulations were also generated using the same 279 population parameters. Overall, and in agreement with our previous analyses, our results suggest 280 a small overlap between neutral and non-neutral peaks for weak drivers (figure 2c and S1f) and 281 highly significant driver predictability when the predicted driver effect was larger than our 282 (narrow) neutral-effect distribution ( Figure 2c ,d and S1g-i). For instance, for simulated 283 populations of 10,000 cell without projection (0 < simulated s < 33) and 1000x coverage our 284 method provided accurate driver detections when the predicted effect was larger than k=1.29 285 with |D| c~5 0 mutations compared to 444.5 for random. These results are directly comparable to 286 our previous analyses, considering the new mutation rates. Similarly, for a projected cell 287 population of 1,000,000 cells, our method provided accurate driver detection for projected 288 selection coefficient s* > 0.05 ( Figure 2d ). Larger population projections typically decreased the 289 predicted effect k* and selection coefficient s*, but did not affect our method's ability to detect 290 drivers ( Figure S1k ) as these projections also decreased the standard deviation of our neutral-291 effect distribution (predicted k* for neutral effect peaks). When we combined 140 neutral with 292 360 non-neutral simulations, drivers with medium final VAF showed the highest correlation 293 between simulated selection coefficients and our method's predicted scalar k effects (r=0.60, 294 We also tested the behavior of the estimator for (Eq. 6) on non-g-hitchhiking mutations (i.e. 304 when the assumption that the mutations are generational hitchhikers is not satisfied). For this 305 purpose, we used coalescent theory to estimate the variation in density of mutations across the 306 VAF spectrum for a variety of models (see Supplement). We first analyzed the behavior in a 307 constant-size population, and then in populations with increasing and decreasing exponential 308 growth. Our analysis shows that the growth indicator does not qualitatively change its behavior 309 in this context, so that negative values continue to represent periods of negative growth, and 310 large positive values represent periods of positive growth. However, here we expect a small 311 positive value in the case of zero growth (Figure 2e Using 993 linear tumors from the PCAWG consortium, we explored the different patterns and 317 dynamics of tumor growth based on our model's assigned growth rates. Tumor "linearity" 318 (where no parental subclone has two or more children subclones) further ensures that tumor subclones do not intermingle and that higher VAF is associated with earlier occurrence. We note 320 that mutational frequency as described in our equations corresponds to 2*VAF, with correction 321 for purity and copy-number variations. These VAF corrections were obtained from PCAWG and 322 are not implemented in any way by our method, which only considers a final mutational 323 frequency. Using our model, each mutation i from sample in our database is assigned a potential 324 positive or negative growth value ri and a driver effect ki. Under ideal conditions, for each 325 sample, a vector of effect-peaks ri-1 × ki corresponds to potential drivers at position i. However, 326 noise, coverage, and growth stochasticity can cause these peaks to represent the potential 327 presence of a nearby driver, especially in low coverage sequenced tumors (see Figure 3a ,b). 328
329
To identify growth patterns across individual tumors, we i) normalized each mutation's growth 330 rate based on the sample's maximum growth value; ii) divided the ordered mutations into 20 331 bins; and iii) applied K-means clustering to the average normalized value per bin. Our results 332 highlighted three main clustering patterns ( Figure 3c ). As expected, most tumors (n=525) 333 showed logistic growth with an increasingly higher growth rate at the beginning and a 334 stabilization at the later stages. For many tumors (n=366), an early high growth period was 335 followed by a stagnation and potential reduction in tumor size. This effect could also be 336 artificially enhanced due to sampling errors for mutations with low VAF (during late tumor 337 progression). The last group of tumors (n=102) showed relatively steady, continuous growth. 338
However, it is uncertain whether this pattern represents tumors that were sequenced early. 339
Further, some types of cancer seemed to prefer specific growth patterns (Figure 3c ). 340 341 single or multiple individual samples. Through positive "growth enrichment", we characterized 343 the degree to which one type of mutation (e.g., TSGs/TP53, nonsynonymous) or region (e.g., 344
TP53) was significantly enriched and associated with periods of positive growth across multiple 345 samples. We then compared each mutation type to random mutations from their respective 346 samples (see Supplementary Methods for details). To confirm whether we could detect any 347 signal of selection at the gene level, we compared positive growth enrichment for mutations 348 between i) the Vogelstein gene list 29 ; ii) a comparable list (in mutational numbers) of randomly 349 selected genes; and iii) a list of assigned drivers from the PCAWG consortium 33,56 . As expected, 350 PCAWG-assigned driver SNVs clearly showed the highest positive enrichment, followed by 351
SNVs that were not individually called by PCAWG as drivers but that fall within the Vogelstein 352 driver gene list (Figure 3d ). We note, however, that our random gene list did show a small 353 positive enrichment, as this list contains several often-mutated genes and potential drivers or 354 mini-drivers. We obtained similar results when we repeated the comparison while considering 355 the difference between additional mutational effect against a random distribution ( Figure S3 ). 356
357
In an effort to better understand the micro-environment of tumor dynamics, the selective forces, 358 and the biological processes that are most keenly affected by tumor progression, we analyzed a 359 list of 1,000 most mutated genes in the PCAWG samples where we identified 293 genes with 360 significant overall association with positive growth (Suppl . Table 1 ). Then we further tested 361 these genes for Gene Ontology (GO) enrichment. As expected, developmental and differentiation 362 processes were highly enriched during periods of positive growth, showing signals for being 363 under positive selection. Interestingly, we found that genes related to multicellular processes 364 showed the highest enrichment based on raw p-value (Figure 3e , Suppl. Based on each mutation's genomic properties (e.g., genomic position, coding vs. non-coding, 369 TSG vs. oncogene, cancer type, and gene ontology annotation), we can examine whether the 370 specific type of mutation (or "mutation element") is statistically enriched during periods of 371 positive growth when compared to random mutations from their respective samples (see 372 supplementary methods). However, the more specifically that we defined a mutation type, the 373 fewer mutations that corresponded to this category. For example, the Vogelstein TSGs in our 374 dataset contain 321 missense and 103 nonsense mutations, whereas TP53 in our dataset contains 375 71 nonsynonymous mutations and 13 nonsense mutations. Unfortunately, for many tumor genes 376 and cancer types, we currently have a small number of mutations, precluding significance in the 377 results. 378 379 A recent study by Kumar et al. suggested that high-impact mutations should have more clear 380 positive effects on tumor growth when they are located in TSGs versus oncogenes 38 . This is 381 expected, as generally a "defected" oncogene with reduced expression should not favor cancer 382 progression. To better understand the behavior of TSGs and oncogenes, we tested for positive 383 enrichment of synonymous, non-synonymous, premature stop, promoter, and intronic mutations 384 ( Figure 4 ). As expected, our results showed significant enrichment of missense and nonsense 385 mutations in TSG regions. During periods of positive growth, 45 nonsense and 128 missense mutations corresponded to an average of 37.4 and 117.96 random mutations, respectively (100 387 bootstraps replicates, p values=7.823348e-30 and 1.632649e-23). Interestingly, promoter and 388 intronic regions also showed a significant positive effect on tumor growth, suggesting that some 389 non-coding mutations in TSGs might favor positive growth (Figure 4a) . 390
391
In the case of oncogenes, we did not find significant enrichment of missense mutations, but we 392 did find significant association between their promoter regions and positive growth (Figures 4b) . 393
This might be due to many reasons including the pancancer nature of our analysis, lack of power 394 and small sample size, our modeling assumptions, or the noise due to low sequencing coverage 395 per tumor sample. However, many genes including oncogenes might be under negative selection, 396 with only a small subset of their respective mutations being favorable to cancer growth. 397
Moreover, high-impact mutations in oncogenic regions do not necessarily favor tumor growth. 398
Indeed, our data contain only four nonsense mutations in oncogenic regions. Some oncogenes 399 such as MET and CTNNB1 showed slight overall negative enrichment, but their nonsynonymous 400 mutations, especially in specific cancers, showed enrichment during periods of positive growth 401 ( Figure S4 ). 402
403
To detect mutations during positive growth periods, we applied our model to individual types of 404 mutations (i.e., missense, synonymous, intronic, nonsense, and promoter) for each Vogelstein 405 gene. Overall, our results identified various mutation elements including promoters, nonsense, 406 and missense with significant effects (Figure 4c ). Interestingly, synonymous BLC2 mutations 407 that occurred near an early positioned mutational hotspot were significantly associated with 408 positive growth (Figures 4c and S5 ). Synonymous mutations are not generally considered to be important in cancer; however, previous studies have reported recurrent synonymous F17F 410 mutations in BLC2-like 12, where regulatory hsa-miR-671-5p alters the gene's expression 45 In general, the predicted peaks of our model mapped very closely to mutations from known 421 cancer genes ( Figure 5 ). Deep valleys followed by the highest growth peaks corresponded with 422 close approximation to the three missense mutations from known cancer genes (IDH1, IDH2, 423 and FLT3, p-value < 2.2e-16). Thus, in agreement with previous studies 35, 36 , the derived growth 424 patterns suggested three to five major genetic hits from cancer mutations in order to render tumor 425 growth permanent. 426
427
Additionally, we used all the mutations in our previous database to evaluate those in the deeply 428 sequenced AML in order to identify new candidates associated with positive growth. As a result, 429 we further identified five additional candidates from the ultra-deep AML sample that belong to 430 genomic elements associated with positive growth (Figure 5d ). These additional candidates 431 consist of four missense mutations (SRCAP, CPS1, GLI1, and COL18A1) and one intronic mutation (MAP3K1), which appeared to align near observed, previously unexplained periods of 433 initial growth. Previous recent studies have also linked CPS1 and GLI1 to various cancers 57-60 . 434 Finally, based on our PCAWG database, for each driver candidate we detected possible positive 435 enrichment across varying effect ranges [0.9, 1.1, 1.3, 1.5, 1.7, 1.9, and 2.1] ( Figure S6) . 436
Indicatively, our independent estimation of mutational effect suggested a high correlation when 437 compared to the calculated effect using the deep sequenced model AML tumor ( Figure S6) . 438 439 440
Discussion 441
Most approaches to identify driver candidates are based on recurrent mutations and large 442 cohorts 23 . More recently, studies have probed tumor selection either through deviation from 443 background metrics or by using VAF distribution to quantify the subclonal effect 16, 19, 22, 61, 62 . 444
Here, we present a framework that models tumor progression using generational hitchhikers and 445 localized time re-optimizations using mutational frequencies from individual samples to i) 446 determine periods of positive or negative growth, ii) suggest the presence of candidate drivers 447 and estimate their effect on tumor progression, and iii) detect genomic regions or mutation 448 elements that are associated with positive or negative growth periods. Overall, our work 449 highlights the importance of whole genome deep sequencing for modelling tumor progression. 450 451 When we applied our framework to 993 individual tumors from the PCAWG consortium, our 452 growth analysis indicated different growth patterns across cancer types, including steady growth, 453 sigmoidal growth, and modes of stagnation. Determining tumor progression can be useful in 454 progression (VAFs used by our method typically represent past growth, as latest mutations tend 456 to have undetected frequency in our sample). Additionally, we identified several biological 457 processes significantly affected by tumor progression, including genes involved in 458 multicellularity. These results might indicate an evolutionary transition during tumor progression 459 from multi-cell functionality to single-cell selection. 460
461
As expected, we found significant enrichment of known PCAWG drivers, Vogelstein cancer 462 genes, and nonsense and missense mutation TSGs during periods of positive growth. In 463 accordance with some previous studies 41-44 , our results also suggested that a small proportion of 464 intronic mutations could affect TSGs (but not oncogenes), whereas some synonymous mutations 465 could affect oncogene (but not TSG) expression. Even though defective splicing in TSGs or 466 changes in the negative regulation of oncogenes are not entirely unexpected 45 , non-coding 467 mutations are not generally considered to be major driver events in tumor progression. Thus, it is 468 possible that our results are subject to analytical (e.g., model parametrization, initial parameters, 469 window size selection, low sequencing coverage, sample size) and biological (e,g, hitchhiking) 470 error. 471 472 Using variant allele frequency to quantify driver effects and tumor progression can be 473 challenging. Our analysis might be subject to different types of bias, including sequencing noise, 474 growth stochasticity, model parameterization, low sequencing coverage, tumor ploidy, 475 subclonality, and a low number of tumor samples per cancer or mutational element. Under a 476 neutral model, our method would still detect some growth peaks or suggest the presence of weak 477 drivers. These are false positive predictions, possibly due to noise which results in various signal perturbations in the VAF spectrum, or potential genetic drift. Moreover, our model does not 479 consider the potential effects from deleterious passenger mutations or sequencing errors on the 480 VAF spectrum. However, we consider that -if not depleted-most deleterious mutations should 481 have a small VAF in our sequenced sample. Similarly, we expect that sequencing errors tend to 482 produce spurious mutations of extremely low VAF, which are ignored by our framework. 483
Although some researchers are skeptical of the plausibility of "VAF quantification" 20,63 , recent 484 analyses have also confirmed that it can be achieved even at low sequencing coverage 16 dependent on the effect of the fitness mutation in the population. We consider a simple 525 population of cancer cells that grows exponentially N(t) = e I1 ; for simplicity, we assign one mutation 526 per cell division. At the time of biopsy T, the frequency of a mutation occurring at time tn would be equal 527 to n (T, t n ) = e r(T−t n ) e rT = e −rt n . At time t1, a mutation occurs that increases the growth rate r of the 528 specific subpopulation by a scalar multiplier k, such that the new population is now expanding as N F = 529 e sI1 T . Thus, at the time of biopsy T=t1+t2, we expect a generational (g-) "hitchhiking" mutation that 530 occurred at time tm < t1 to have a frequency equal to g (T, t m ) = e r(T−t m ) + N F -e rt 2 N tot , where Ntot is the total 531 number of cells (or mutations) and NF is the number of cells that contain the fitness mutation that 532 occurred at t1 and expanded for t2. Therefore N F = krt 2 . In a) we show the mutational frequencies at 533 the time of biopsy T for two growth models; one neutral and one with a fitness mutation 534 occurring at time t1=tfg . Hitchhiking mutations 'b' ("blue"), 'r' ("red"), as well as passenger 535 mutations 'g' ("green") and 'y' ("yellow"), also occur at different time points. b) Under an 536 exponential model with a fitness mutation occurring at time t1=tfg, hitchhikers 'b' and 'r' show an 537 increased frequency compared to neutral, subject to time and effect of the fitness mutation. 538
Passenger mutations 'y' and 'g' that occurred before or with the fitness mutation, but on a 539 different cell lineage, end up with lower frequencies. We characterize mutations 'b' and and 'r' 540 as generational (g-) hitchhikers since they mark the population's generational growth. neutral and non-neutral simulations, we simulated 360 non-neutral and 140 neutral tumor 562 progressions, with a populations size of 10000 cells. Then, we adjusted our effect predictions to 563 account for a larger population with effect size equal to 1,000,000. In addition, we also adjusted 564 the simulated selection coefficient s* for the same population size. In this figure we show the 565 correlation between the simulated adjusted coefficient '1+s*' against our adjusted predicted k*. 566
By including both neutral and non-neutral simulations in our sample Pearson correlation was 567 r=0.6. In d) after ranking simulated driver coefficients s* for every non-neutral simulation 568 (adapted from Williams et al), we used a sliding window of 20 ranked simulations to estimate the absolute median distance (and 95% deviation) between the simulated and predicted driver within 570 every window of 20 ranked simulations. Dotted lines represent a 2×σ deviation (95%). When 571 our simulated selection coefficient was stronger than 0.05* our driver detection became highly 572 accurate. Blue line represents absolute median distance for random predictions (444.5), while 573 black lines represent the median standard error for these expectation (24.5). Simulated 574 coefficients s* have been projected for a population with effect size of 1,000,000. In e) Using 575
Kingman's coalescent theory, for a length of time T W with n lineages, we show that the growth 576 ̂ estimator remains qualitatively unchanged (positive or negative) even for non g-hitchhikers. 577
By approximation, the mutational density z within windows [1/n 1/(n − 1)), whose lengths 578 are L W is equal to z =~• consortium we expect an under-selection mutation to be associated with periods of positive 591 growth (see supplementary methods). We compared several mutation types (driver mutation, 592 mutation within geneX, within GO categoryX), to a random distribution from their respective 593 sample for association with positive growth. a-b) we show the i) averaged growth progression, 594 ii) mutational growth and iii) mutational effect, for a single low coverage CNS-oligo tumor and a 595 single low coverage thyroid adenocarcinoma tumor without any PCAWG-identified drivers. 596
Green asterisks denote the ordered position of a PCAWG-predicted driver within the sample. 597 Yellow asterisks denote a growth peak and putative driver presence. In c) we derived three main 598 growth patterns (steady growth, sigmoid growth, stagnation/shrinkage) for 993 linear tumors, as 599 they were grouped using a k-means clustering algorithm. Various cancer types showed specific 600 enrichment or depletion for the three clusters d) PCAWG drivers and Vogelstein genes showed 601 significant positive growth enrichment compared to a list of random highly mutated genes. e) We 602
show the GO enrichment for the 20 most affected biological processes, when we use 293 genes, 603 significantly associated with periods of positive growth. 604 605 606 607 608 In a) we show the averaged growth progression for an AML deep sequenced tumor. We ordered 622 the sample's mutations from highest to lowest frequency and divided them into bins of 200 623 mutations. Three cancer mutations hit the tumor to establish a permanent growth (cancer 624 mutations denoted by green bars). In b) we plot the mutational growth ri-1 for each mutation 625 across tumor progression. The three cancer genes (IDH1-missense, FLT3-missense, IDH2-626 missense) aligned well with 3 of our top 5 growth peaks (p-value < 2.2e-16). Candidate driver 627 mutations -denoted by yellow bar-that we identified from our PCAWG database as being 628 associated with positive growth (see also 'd)') aligned well with early -previously unjustified 629 growth peaks. In c) we show each mutation's effect in tumor progression. Effect peaks 630 corresponds to putative drivers. d) By using our PCAWG database from our previous analysis, 631 we tested which mutations from the deep sequenced sample were associated with positive 632 growth. Overall, we found 6 mutation types that showed positive enrichment across 993 633 PCAWG tumors including TP53-missense (appeared during metastasis), IDH1-missense, 634 COL18A1-missense, CPS1-missense, GLI1-missense and SRCAP-missense. Missense TP53 635 and SRCAP mutations are not included in graph (b) as they were metastatic mutations. For 636 association with positive growth we tested all missense mutations (eg CPS1-missense), and 637 every mutation in the sample from Vogelstein cancer genes (eg. NOTCH2-Intron). 638 639 640 641
